Compare Gilead Sciences, Inc. (GILD) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Global Payments Inc — how do they compare? Gilead Sciences, Inc. trades at $137.07 (market cap $168.35B), while Global Payments Inc trades at $84.62 (market cap $22.72B). The key difference: Gilead Sciences, Inc. is far larger — about 7.4× Global Payments Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | GPN | |
|---|---|---|
Market Cap | $168.35B | $22.72B |
Sector | Health | Industrials |
52-Week High | $155.80 | $90.01 |
52-Week Low | $110.56 | $62.47 |
Enterprise Value | $191.42B | $40.87B |
Dividend Yield | 2.42% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Global Payments (GPN) trades at $86.13, up slightly by 0.01% today, with a bullish technical signal from moving averages and strong quarterly EPS beats. The company reported Q2 2026 EPS of $3.46, exceeding expectations, but faces headwinds with a negative net income margin of -9.15% in 2026. Recent news highlights Genius platform momentum driving earnings growth, though full-year revenue guidance was trimmed due to Middle East challenges.
Outlook remains cautiously optimistic with a consensus price target of $96.67, offering 12% upside, supported by analyst buy ratings at 58.7%. Key risks include margin pressure from rising costs and intense fintech competition, while institutional interest persists with recent investments like Delta Global Management's $1.74 million stake in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
